All News

ACOG 2026: Kathryn Miele, MD, discusses syphilis titer interpretation, discordant results, partner treatment, and practical resources for primary care clinicians.

The approval indicates ocrelizumab for RRMS in patients older than 10 years who weigh 55 pounds or more and is supported by data from the OPERETTA II study.

Highlights include clinical gaps in menopause care, postpartum prevention, cervical cancer screening, pregnancy-related infection, and GLP-1 RA exposure.

Pneumococcal vaccination in pregnancy remains underused in high-risk patients. Maria Marcos, MD, reviews new data, barriers to uptake, and practical vaccination steps for primary care.

Bariatric surgery was associated with lower 2-year costs than GLP-1 therapy in adults with obesity and type 2 diabetes, according to new real-world data.

Jill Liss, MD, outlines how updated evidence, risk stratification, and newer nonhormonal agents can help PCPs confidently manage VMS in everyday practice.

ACOG 2026: James A. Simon, MD, discusses off-label evidence for elinzanetant in breast cancer survivors on anti-estrogenic therapy.

DDW 2026 data show real-world, 52-week IBD outcomes with risankizumab and upadacitinib, including persistence, fewer switches, and hospital visits.

ACOG 2026: James A. Simon, MD, discusses what the results mean for frontline clinician confidence in prescribing the non-hormonal VMS treatment.

FDA updates include oral GLP-1 therapy, HIV regimen, gene therapy for hearing loss, and diabetes technology advances.

Network meta-analysis suggests lumateperone add-on therapy improves MDD symptoms most, with minimal weight gain and placebo-like akathisia risk.

Late-breaking data presented at ACOG 2026 showed GLP-1 RA exposure before or during early pregnancy was not associated with hypertensive disorders of pregnancy.

ACOG 2026: Jill Liss, MD, details how primary care physicians can safely initiate hormone therapy, manage menopause counseling in brief visits, and more.

ACOG 2026: The new guidance formally introduces clinician-ordered self-collected HPV testing as an option for cervical cancer screening.

ACOG 2026: Genevieve Neal-Perry, MD, discussed her clinical experience with elinzanetant for the treatment of VMS associated with menopause.

A nationally representative study found 71.5% of US women aged 21-49 years were open to HPV self-collection, including 9.7 million who were underscreened or never screened.

Hear from the presenting investigator of late-breaking research presented at ACOG 2026 that found over 80% of pregnancy-related infection deaths were preventable.

Hot flashes and night sweats are just 2 of the myriad symptoms associated with menopause. Click through a quick refresher on the transition and effective treatments.